顺铂/肾上腺素(Cisplatin/Epinephrine) - 药物靶点：ADRA1 x DNA x β-adrenoceptors_专利_临床

概要

基本信息

药物类型

小分子化药

别名

CDDP TI、IntraDose-CDDP

靶点

ADRA1 x DNA x β-adrenoceptors

作用机制

ADRA1激动剂(肾上腺素能受体α-1家族激动剂)、DNA抑制剂(DNA抑制剂)、β-adrenoceptors激动剂(β-肾上腺素能受体家族激动剂)

+ [3]

治疗领域

肿瘤消化系统疾病呼吸系统疾病+ [1]

在研适应症-

非在研适应症

乳腺癌食管癌头颈部肿瘤+ [7]

原研机构

Novartis Pharma AG

在研机构-

非在研机构

Novartis Pharma AG

Novartis AGMatrix Pharmaceutical, Inc.

最高研发阶段无进展临床3期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评孤儿药 (美国)

结构

分子式Cl2H6N2Pt

InChIKeyWCLAIRSNZFYZAT-UHFFFAOYSA-N

CAS号15663-27-1

查看全部结构式(2)

关联

4

项与顺铂/肾上腺素相关的临床试验

JPRN-UMIN000009011 / Completed

JIVROSG-0808(RADPLAT Japan, maxillary carcinoma-II) Cisplatinum (CDDP) transarterial chemoradiptherapy for patients with maxillary carcinoma, pahse II study - JIVROSG-0808 CDDP transarterial chemoradiptherapy for patients with maxillary carcinoma, pahse II study

开始日期2012-10-01

申办/合作机构

National Cancer Center Research Institute

NCT00022217 / Unknown status临床2期

A Phase II Activity And Safety Study Of IntraDose (Cisplatin/Epinephrine Injectable Gel) When Given In Combination With Systematic Chemotherapy Paclitaxel And Carboplatin In The Treatment Of Patients With Squamous Cell Carcinoma Of The Head And Neck At First Relapse

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of cisplatin-epinephrine injectable gel plus paclitaxel and carboplatin in treating patients who have recurrent head and neck cancer.

开始日期2000-11-01

申办/合作机构

Matrix Pharmaceutical, Inc.

NCT00003044 / Unknown status临床2期

A Two-Stage Phase II Safety and Efficacy Study of IntraDose (Cisplatin/Epinephrine) Injectable Gel (MPI 5010) Administered to Patients With Unresectable Primary Hepatocellular Carcinoma

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of cisplatin and epinephrine administered directly into the tumor in treating patients who have primary liver cancer that cannot be removed during surgery.

开始日期1996-09-01

申办/合作机构

Matrix Pharmaceutical, Inc.

100 项与顺铂/肾上腺素相关的临床结果

登录后查看更多信息

100 项与顺铂/肾上腺素相关的转化医学

登录后查看更多信息

100 项与顺铂/肾上腺素相关的专利（医药）

登录后查看更多信息

232

项与顺铂/肾上腺素相关的文献（医药）

2024-03-08·Alternative therapies in health and medicine

Related Factors of CRKP Infection in Neurosurgery and Comparison of Therapeutic Effects of Tigecycline Versus Polymyxin B for CRKP Infection.

Article

作者: Li, Yang ; Wang, Shiyong ; Yu, Haohui ; Li, Ning ; Liu, Shengming ; Feng, Yongjian ; Chen, Huixuan

ObjectiveThis paper aimed to identify the factors related to Carbapenem-resistant Klebsiella pneumoniae (CRKP) infection in neurosurgical patients, and to compare the therapeutic effects of tigecycline versus polymyxin B against CRKP infection, so as to provide a reliable reference for neurosurgery in future prevention and treatment of CRKP infection.MethodsOne hundred and fifty cases of KPN treated in the neurosurgery department of our hospital from January 1, 2019 to December 31, 2021 were selected, 50 of which were found to be infected with CRKP and the other 100 were detected with carbapenem-sensitive Klebsiella pneumoniae (CSKP) by culture, analysis of factors associated with infection with CRKP. Subsequently, CRKP-infected patients were randomized into a group treated with Ti (group Ti) and a group treated with PB (group PB). The clinical efficacy, bacterial clearance, adverse reactions, and pre- and post-treatment hepatorenal function were comparatively analyzed.ResultsBased on the Logistic regression analysis, tracheal intubation (or mechanical ventilation), combination of multiple underlying diseases, presence of impaired consciousness, and use of carbapenem antibiotics are independent risk factors for CRKP infection (P < .05). Ti and PB groups had no evident differences in clinical efficacy and bacterial clearance (P > .05); however, Ti group presented a worse hepatorenal function and a higher incidence of adverse reactions than PB group (P < .05).ConclusionsTracheal intubation (or mechanical ventilation), multiple underlying diseases, consciousness disturbance, and use of carbapenem antibiotics are related factors affecting CRKP infection in neurosurgical patients. Both Ti and PB have excellent therapeutic efficacy, but the former has more obvious toxicity and side effects.

2024-02-01·iScience

Heat-killed Mycobacterium tuberculosis induces trained immunity in vitro and in vivo administered systemically or intranasally

Article

作者: Bravo-Robles, Laura ; Mata-Martínez, Pablo ; Bıçakcıoğlu, Gülce ; Del Fresno, Carlos ; Fernández-Pascual, Jaime ; López-Collazo, Eduardo ; Zapata-Fernández, Gabriela ; Bergón-Gutiérrez, Marta ; Minute, Luna ; Aguiló, Nacho ; Terrón, Verónica

Trained immunity (TI) represents a memory-like process of innate immune cells. TI can be initiated with various compounds such as fungal β-glucan or the tuberculosis vaccine, Bacillus Calmette-Guérin. Nevertheless, considering the clinical applications of harnessing TI against infections and cancer, there is a growing need for new, simple, and easy-to-use TI inducers. Here, we demonstrate that heat-killed Mycobacterium tuberculosis (HKMtb) induces TI both in vitro and in vivo. In human monocytes, this effect represents a truly trained process, as HKMtb confers boosted inflammatory responses against various heterologous challenges, such as lipopolysaccharide (Toll-like receptor [TLR] 4 ligand) and R848 (TLR7/8 ligand). Mechanistically, HKMtb-induced TI relies on epigenetic mechanisms in a Syk/HIF-1α-dependent manner. In vivo, HKMtb induced TI when administered both systemically and intranasally, with the latter generating a more robust TI response. Summarizing, our research has demonstrated that HKMtb has the potential to act as a mucosal immunotherapy that can successfully induce trained responses.

2024-02-01·Cell Reports Medicine

TwinF interface inhibitor FP802 stops loss of motor neurons and mitigates disease progression in a mouse model of ALS

Article

作者: Yan, Jing ; Bading, Hilmar ; Hellwig, Andrea ; Wang, Yu Meng

Toxic signaling by extrasynaptic NMDA receptors (eNMDARs) is considered an important promoter of amyotrophic lateral sclerosis (ALS) disease progression. To exploit this therapeutically, we take advantage of TwinF interface (TI) inhibition, a pharmacological principle that, contrary to classical NMDAR pharmacology, allows selective elimination of eNMDAR-mediated toxicity via disruption of the NMDAR/TRPM4 death signaling complex while sparing the vital physiological functions of synaptic NMDARs. Post-disease onset treatment of the SOD1^G93A ALS mouse model with FP802, a modified TI inhibitor with a safe pharmacology profile, stops the progressive loss of motor neurons in the spinal cord, resulting in a reduction in the serum biomarker neurofilament light chain, improved motor performance, and an extension of life expectancy. FP802 also effectively blocks NMDA-induced death of neurons in ALS patient-derived forebrain organoids. These results establish eNMDAR toxicity as a key player in ALS pathogenesis. TI inhibitors may provide an effective treatment option for ALS patients.

100 项与顺铂/肾上腺素相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乳腺癌	临床3期	美国	Novartis AG	-
乳腺癌	临床3期	-	Novartis Pharma AG	-
食管癌	临床3期	-	Novartis Pharma AG	-
食管癌	临床3期	美国	Novartis AG	-
食管癌	临床3期	欧盟	-	-
黑色素瘤	临床3期	欧洲	Novartis AG	-
黑色素瘤	临床3期	美国	Novartis AG	-
黑色素瘤	临床3期	-	Novartis Pharma AG	-
乳腺癌	临床1期	欧洲	Novartis AG	-
肝癌	临床1期	-	Novartis Pharma AG	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ChiCTR1900024488 (ESMO2020) 人工标引	临床1期	实体瘤	9	cisplatin 40mg/m2+niraparib 100mg+sintilimab 200mg	(簾範憲憲襯壓淵餘廠鏇) = 觸積鏇範廠鏇繭襯鏇鹽範鏇憲膚構簾襯鑰鹹艱 (鹽築衊廠範窪遞鏇鏇鏇 )	积极	2020-09-17
				cisplatin 60mg/m2+niraparib 100mg+sintilimab 200mg	(簾範憲憲襯壓淵餘廠鏇) = 網遞顧獵齋蓋壓製積遞範鏇憲膚構簾襯鑰鹹艱 (鹽築衊廠範窪遞鏇鏇鏇 )
WCLC2018	N/A	恶性胸膜间皮瘤	27	Ganetespib	(艱膚憲淵餘醖餘醖鏇觸): hazard ratio = 0.32 (95% CI, 0.11 ~ 0.95), P-Value = 0.04	-	2018-09-25
				Pemetrexed and Cisplatin/Carboplatin Chemotherapy
WCLC2015	N/A	广泛期小细胞肺癌	62	Irinotecan/cisplatin (IP)	(壓廠糧餘願鬱廠製餘顧) = 衊廠齋鏇選膚選齋繭淵鑰築選鬱鏇膚網選齋蓋 (築襯衊齋製鬱醖獵夢範 ) 更多	-	2015-09-08
				Etoposide/cisplatin (EP)	(壓廠糧餘願鬱廠製餘顧) = 膚築夢蓋鑰顧壓遞選顧鑰築選鬱鏇膚網選齋蓋 (築襯衊齋製鬱醖獵夢範 ) 更多